HLB PepHLB펩
196300 · KOSDAQ · ₩196300 · HLB펩
- Market cap
- ₩39B
- Enterprise value
- ₩55B
- P/E
- —
- P/B
- 1.7×
- Dividend yield
- 0.0%
- ROE
- −0.8%
- Net margin
- −3.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−57.0% from the high
₩3,510Today: ₩4,015 – ₩4,145₩9,530
Returns
- 1W−4.2%
- 1M−26.7%
- 3M+6.4%
- 6M−42.7%
- YTD−42.7%
- 1Y−39.5%
- Volume today
- 10,923
- 0.1× the 20-day average
- Traded today
- ₩44M
- Listed shares
- 9,493,947
- EPS (12 months)
- −₩20
- Earnings yield −0.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: Only a routine corrected filing about a facility investment. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat-4.7% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
HLB Pep stock overview
HLB Pep (HLB펩, KRX: 196300) is listed on KOSDAQ, in the Biotech & Pharma sector. HLB Pep (에이치엘비펩) develops peptide bio-materials for industrial and pharmaceutical use, along with innovative peptide drug candidates targeting unmet medical needs such as drug-resistant breast cancer, type 2 diabetes, obesity, infections and ulcerative colitis. Its shares closed at ₩4,100 on Oct 28, 2026, down 1.09% on the day, giving it a market value of ₩39B.
Key facts
- Market cap
- ₩39B
- Sector
- Biotech & Pharma
- Latest price change
- −1.09%
- As of
- Oct 28, 2026
- Main business
- HLB Pep (에이치엘비펩) develops peptide bio-materials for industrial and pharmaceutical use, along with innovative peptide drug candidates targeting unmet medical needs such as drug-resistant breast cancer, type 2 diabetes, obesity, infections and ulcerative colitis.
Quick answers about HLB Pep
- What does HLB Pep do?
- HLB Pep (에이치엘비펩) develops peptide bio-materials for industrial and pharmaceutical use, along with innovative peptide drug candidates targeting unmet medical needs such as drug-resistant breast cancer, type 2 diabetes, obesity, infections and ulcerative colitis. The company supplies research peptides to universities, hospitals, pharmaceutical companies and research institutes, and offers CDMO services from development through GMP manufacturing at its Jangseong and Osong facilities.
- What is the market cap of HLB Pep?
- The market capitalisation of HLB Pep was ₩39B at the close on Oct 28, 2026.
- Who are the largest shareholders of HLB Pep?
- According to the latest official filings, the largest reported holders are HLB Genex (42.46%, as of Aug 20, 2026); Coas (8.85%, as of Mar 20, 2025); Kim Jae-il (8.28%, as of Jun 16, 2025).
- When is the next earnings report from HLB Pep?
- Korean companies rarely announce results dates in advance. Based on when HLB Pep filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
HLB Pep (에이치엘비펩) develops peptide bio-materials for industrial and pharmaceutical use, along with innovative peptide drug candidates targeting unmet medical needs such as drug-resistant breast cancer, type 2 diabetes, obesity, infections and ulcerative colitis. The company supplies research peptides to universities, hospitals, pharmaceutical companies and research institutes, and offers CDMO services from development through GMP manufacturing at its Jangseong and Osong facilities.
Written by AI from the company's latest annual report.
- Korean name
- HLB펩
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 심경재 (단독 대표)
- Founded
- May 2000
- Listed
- Dec 2016
- Listed shares
- 9,493,947
- Fiscal year ends
- Month 12
- Website
- www.hlbpep.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- [Corrected] New Facility Investment, etc.Oct 29, 2026
- Amended: Investor relations (IR) eventOct 12, 2026
- Investor relations (IR) eventOct 12, 2026
- Material Matters Report (Decision on Acquisition of Own Convertible Bonds Before Maturity)Sep 9, 2026
- Insider shareholding reportAug 20, 2026
Titles in Korean until English translations are added.
Also known as: HLB Pep / HLB펩 / 196300 / KRX:196300
Source: KRX statistical information